The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

Figure 1

Figure 2

Figure 3

Five-year and eight-year survival of patients after different surgical outcomes

	Five-year survival	Eight year survival	p
Surgery - R0 resection	62.5%	62.5%	P < 0.0001
NACT -R0 resection	20.6%	17.1%
Surgery - R1 resection	38.9%	27.8%	P < 0.0001
NACT -R1 resection	16.7%	11.1%
Surgery - R2 resection	15.5%	0%	P < 0.0001
NACT -R2 resection	0%	0%
Inoperable disease	0%	0%	-

Factors correlated with survival on multivariate analysis

	p
Age (years)
< 60	0.775
≥ 60
Histology
High grade serous	0.370
Other histology
Performance status
0 or 1
> 1	0.003
Extent of residual disease
R0
R1	< 0.0001
R2
Therapy
Primary surgery
NACT	0.038

The characteristics of patients and surgical outcomes

	Primary surgery N = 80	NACT N = 80	p
Age (years)	60.2	64.8	0.006
High grade serous	43 (54%)	53 (66%)	0.307
Performance 0 or 1	66 (83%)	32 (40%)	< 0.0001
>1	14 (17%)	48 (60%)
R0 resection	16 (20%)	34 (42%)	0.011
R1 resection	18 (23%)	18 (22%)	1.0
R2 resection	46 (57%)	11 (14%)	< 0.0001
Inoperable	-	17 (21%)	-
PFS (months)	17.7	14.1	0.213
OS (months)	31.6	24.8	0.012

Factors correlated with survival on univariate analysis

	p
Age (years)
< 60	0.008
≥ 60
Histology
High grade serous	0.066
Other histology
Performance status
0 or 1
> 1	< 0.0001
Extent of residual disease
R0
R1	< 0.0001
R2
Therapy
surgery Primary
NACT	0.012